Treatment experience with nonseminomatous testicular cancer in patients with stage II and stage III disease
Open Access
- 1 September 1981
- Vol. 48 (5) , 1110-1115
- https://doi.org/10.1002/1097-0142(19810901)48:5<1110::aid-cncr2820480511>3.0.co;2-3
Abstract
Thirty‐eight patients with nonseminomatous testicular cancer were treated with cis‐platinum, bleomycin, and vinblastine in combination without a prolonged maintenance phase. Twenty‐six patients with Stage III disease were treated. Seventy‐six percent of those patients treated achieved, complete remission. At a median survival time of 30 months, no patient who achieved a complete remission has relapsed. Twelve Stage II patients given adjuvant therapy remain free of disease at a median time of 23 months. Markedly elevated serum lactate dehydrogenase levels and massive disease were common findings in the patients who did not achieve complete remission. One drug death occurred secondary to sepsis. Symptoms of depression and anxiety were significant dose‐limiting factors in this group of patients.This publication has 7 references indexed in Scilit:
- Vinblastine, bleomycin and cis-diamminedichloroplatinum in the treatment of advanced testicular carcinoma: Possible importance of longer induction and shorter maintenance schedulesThe American Journal of Medicine, 1980
- Testicular Germ-Cell Neoplasms: Recent Advances in Diagnosis and TherapyAnnals of Internal Medicine, 1979
- Germ cell tumors (II). VAB II in metastatic testicular cancerCancer, 1978
- Carcinoma of the testisCancer, 1977
- Surgical Management of Testis TumorJournal of Urology, 1974
- Surgical treatment of non-seminomatous germinal testes tumorsCancer, 1973
- Effects of Combined Drug Therapy on Metastatic Cancer of the TestisJAMA, 1960